Investors Focus on Fortune-Making Immuno-Oncology Race

On Tuesday's edition of Market Checkup, Motley Fool health-care analyst David Williamson looks at the biggest winners and losers in health-care stocks today.

Bristol-Myers Squibb took a hit recently, when it was unclear about its timeline for advancing its lead immuno-oncology drug candidate Nivolumab. While investors are excited about how this may pair up with Bristol's already approved drug Yervoy, management is taking a cautious pace while it tests out a number of different drug pairings. This delay has not only put doubt about the pairing in the mind of investors, but it has also given Merck , which has a similar drug in development that would be a direct competitor, a chance to strike.

In this segment, David breaks this competitive race down for investors and discusses what to watch with these two companies in this space.

So what's the best way for investors to play the biotech space today?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that Big Pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

The article Investors Focus on Fortune-Making Immuno-Oncology Race originally appeared on

David Williamson owns shares of Merck. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story